Heparan sulfate proteoglycans and their modification as promising anticancer targets in hepatocellular carcinoma

Area of Science:

• Oncology
• Biochemistry
• Extracellular Matrix Biology

Background:

• Hepatocellular carcinoma (HCC) remains a leading cause of cancer death globally.
• Current HCC treatments face challenges with drug resistance, necessitating novel therapeutic strategies.
• Heparan sulfate proteoglycans (HSPGs) are key extracellular matrix components involved in tumor progression.

Purpose of the Study:

• To review the role of enzymes and compounds associated with HSPGs in HCC pathogenesis.
• To identify potential novel therapeutic targets within the HSPG pathway for HCC treatment.
• To discuss how HSPG modulation could overcome therapeutic resistance in HCC.

Main Methods:

• Literature review of enzymes (heparanase, MMP-9, sulfatase-2) affecting HSPGs.
• Analysis of HSPG degradation products (glypican-3, syndecan-1) in HCC.
• Synthesis of current understanding of HSPG involvement in HCC progression and invasion.

Main Results:

• Enzymatic degradation of HSPGs by heparanase, MMP-9, and sulfatase-2 promotes HCC cell invasion.
• HSPG degradation products like glypican-3 and syndecan-1 are implicated in enhancing tumor progression.
• Dysregulation of HSPGs contributes significantly to the pathogenicity of HCC.

Conclusions:

• Targeting enzymes that modify HSPGs or their degradation products presents a promising strategy for novel HCC therapies.
• Understanding HSPG-related mechanisms is crucial for developing drugs that overcome resistance.
• HSPG pathway modulation offers a potential avenue for effective HCC treatment.